NCT04279405View on ClinicalTrials.gov

A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

June 1, 2023

Conditions
Small Lymphocytic LymphomaLymphoplasmacytic LymphomaMarginal Zone LymphomaMantle Cell LymphomaDiffuse Large B Cell Lymphoma
Interventions
DRUG

YY-20394

YY-20394 80mg tablet administered orally once daily

Trial Locations (1)

Unknown

Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Shanghai YingLi Pharmaceutical Co. Ltd.

INDUSTRY

NCT04279405 - A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies | Biotech Hunter | Biotech Hunter